Diagnosis of prostate cancer: The clinical use of transrectal ultrasound and biopsy

EAU Update Series

Volumn 1, Issue 1, 2003, Pages 9-15

  Djavan, Bob ^a   Remzi, Mesut ^a   Ghawidel, Keywan ^a   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Prostate biopsy; Prostate cancer; Prostate volume; Prostate specific antigen; Repeat prostate biopsy; Transition zone; TRUS

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

DIAGNOSTIC ACCURACY; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; PROSTATE CARCINOMA; RECTUM BIOPSY; REVIEW; STANDARDIZATION; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME;

EID: 1642346132     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9124(03)00004-7     Document Type: Article

References (38)

1. Dijkman GA, Debruyne FM. Epidemiology of prostate cancer. Eur Urol 1996;30:281-95.
2. Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, et al. Prostate specific antigen density of the transitional zone for early detection of prostate cancer. J Urol 1998;160:411-9.
3. Parker SL, Tong T, Bolden S, Winog PA. Cancer statistics. CA Cancer J 1996;46:5-27.
4. Brawer MK. Prostate-specific antigen: critical issues. Urology 1994; 44:9.
5. Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71.
6. Epstein JI, Walsh PC, Sauvageot J, et al. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 1997;158:1886.
7. Norberg M, Egevad L, Holmberg L, et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997;50:562.
8. Stricker HJ, Ruddock LJ, Wan J, et al. Detection of nonpalpable prostate cancer. A mathematical and laboratory model. Br J Urol 1993;71:43.
9. Naughton CI, Smith DS, Humphrey PA, et al. Clinical and pathologic tumour characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 1998;52:808.
10. Levine MA, Ittmann M, Melamed J, et al. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998;159:471.
11. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157:199.
12. Horninger W, Reissigl A, Fink K, et al. Results of a prospective randomised study comparing the prostate cancer detection rates in PSA screening volunteers undergoing 10 vs. 14 transrectal ultrasound guided biopsies. J Urol 1998;159:180 [Abstract 690].
13. Nava L, Montorsi F, Consonni P, et al. Results of a prospective randomised study comparing 6, 12, and 18 transrectal, ultrasound guided, sextant biopsies in patients with elevated PSA, normal DRE and normal prostatic ultrasound. J Urol 1997;157(Suppl):59 [Abstract 226].
14. Chen ME, Troncoso P, Johnston DA, et al. Optimization of prostate biopsy strategy using computer based analysis. J Urol 1997;158:2168.
15. Beurton D, Barthelemy Y, Fontaine E. Twelve systematic prostate biopsies are superior to sextant biopsies for diagnosing carcinoma: a prospective randomized study. Br J Urol 1997;80:239.
16. Karakiewicz PI, Bazinet M, Aprikian AG, et al. Outcome of sextant biopsy according to gland volume. Urology 1997;49:55.
17. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
18. Bazinet M, Karakiewicz PI, Aprikian AG, et al. Value of systematic TZ biopsies in the early detection of prostate cancer. J Urol 1996;155:605-6.
19. Terris MK, Pham TQ, Issa IM, Kabalin JN. Routine TZ and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. J Urol 1997;157:204-6.
20. Morote J, Lopes M, Encabo G, de Torres IM. Value of routine TZ biopsies in patients undergoing ultrasound-guided sextant biopsies for the first time. Eur Urol 1999;35:294-7.
21. Epstein JT, Walsh PC, Sauvageot J, Carter HB. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 1997;158:1886-90.
22. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 1998;159:920-4.
23. Djavan B, Zlotta AR, Remzi NI, Bursa B, Hruby S, Wolfram R, et al. Total and transition zone prostate volume and age: How do they affect the utility of PSA based diagnostic parameters for early prostate cancer detection? Urology 1999;54:846-52.
24. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45:2.
25. Sieber PR, Rommel FM, Agusta VE, et al. Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. J Urol 1997;157:2199.
26. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001;166(3):856-60.
27. Djavan B, Ziotta AR, Ekane S, Remzi M, Kramer G, Roumeguere T, et al. Is one set of sextant biopsies enough to rule out prostate cancer? Influence of transition and total prostate volumes on prostate cancer yield. Eur Urol 2000;38:218-24.
28. Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 1997;158:505-9.
29. Rietbergen JBW, Boeken Kruger AE, Hoedernaeler RF, Bangma CH, Kirkels WJ, Schröder FH. Repeat screening for prostate cancer after 1-year follow up in 984 biopsied men: Clinical and pathological features of detected cancer. J Urol 1998;160:2121-5.
30. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45:2-12.
31. Billebaud T, Villers A, Astier L, Sibert A, Baron JC, Delnas V, et al. Advantage of systematic random ultrasound-guided biopsies. Eur Urol 1992;21:6-14.
32. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 1998;159:920-4.
33. Karakiewicz PI, Hanley JA, Eazinet M. Three-dimensional computer-assisted analysis of sector biopsy of the prostate. Urology 1998; 52:208-12.
34. Bauer JJ, Zeng J, Weir J, Zhang W, Sesterhern IA, Connely RR, et al. Three-dimensional computer-simulated prostate models: Lateral prostate biopsies increase the detection rate of prostate cancer. Urology 1999;53:961-7.
35. Remzi M, Djavan B, Wammack R, Momeni M, Seitz C, Erne B, et al. Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy. Urology 2003;61(1):161-6.
36. Mazal PR, Haitel A, Windischberger C, Djavan B, Sedivy R, Moser E, et al. Spatial distribution of prostate cancers undetected on initial needle biopsies. Eur Urol 2001;39:662-8.
37. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop? J Urol 2001;166: 1679-83.
38. Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Repeat prostate biopsy: Who, how and when? A review. Eur Urol 2002; 42:93-103.